<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308291</url>
  </required_header>
  <id_info>
    <org_study_id>CIP328</org_study_id>
    <nct_id>NCT04308291</nct_id>
  </id_info>
  <brief_title>The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.</brief_title>
  <official_title>The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France (EQOL Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy in glycemic control and the impact on&#xD;
      the quality of life of patients using the MiniMed™ 780G System for the treatment of Type 1&#xD;
      diabetes, in real life settings in France.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local, post-market, non-interventional, prospective, single-arm, multi-center study of&#xD;
      patients pediatric and adult.&#xD;
&#xD;
      The study is conducted according to the same schedule as the routine follow-up of patients:&#xD;
&#xD;
        1. RUN-IN PHASE: Subject will start a run-in phase in an out of hospital setting, as per&#xD;
           standard practice of the site. The objective of the run-in phase is to train the&#xD;
           subjects on the MiniMed™ 780G insulin pump, assess subjects' compliance and ability to&#xD;
           comprehend the study procedures and tolerance of wearing the sensor and transmitter&#xD;
           continuously. It is expected that during the run-in phase the MiniMed™ 780G insulin pump&#xD;
           will be set in Manual mode and all the algorithms are switched off, and baseline&#xD;
           Continuous Glucose Monitoring (CGM) data will be collected. The expected duration of the&#xD;
           run-in phase is approximately 2 weeks. At the end of the run-in phase the MiniMed™ 780G&#xD;
           insulin pump will be set in Auto Mode and the date of activation will be collected and&#xD;
           identified as a start of the study phase. Data from the MiniMed™ 780G insulin pump will&#xD;
           be uploaded in the CareLink™ as per standard practice, before Auto Mode activation.&#xD;
&#xD;
        2. 6 AND 12 MONTHS FOLLOW UP: Follow-up visits will be performed according to the therapy&#xD;
           management standard of care at 6 and 12 months after Auto Mode activation in the study.&#xD;
&#xD;
      Approximately 300 patients (children and adults) will be enrollment in the study in&#xD;
      approximately 32 sites in France.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time in range (TIR)</measure>
    <time_frame>0-6months</time_frame>
    <description>The change in (%) the time spent within range, defined as the proportion of sensor glucose concentration within the target range of 70-180 mg/dL, between baseline and 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score</measure>
    <time_frame>0-6months</time_frame>
    <description>To evaluate the change from baseline in satisfaction score based on the Diabetes Treatment Satisfaction Questionnaire change (DTSQc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Change</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change in quality of life based on the Diabetes Quality of life questionnaire (DQoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemic events Change</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change from baseline in the fear of hypoglycemic events based on the Hypoglycemia Fear Survey (HFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction score</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the treatment satisfaction score based on the Diabetes Treatment Satisfaction Questionnaire status (DTSQs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters changes</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change in glycemic parameters: mean time of sensor glucose values below 70mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters changes</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change in glycemic parameters: mean time of sensor glucose values below 54mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters changes</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change in glycemic parameters: mean time of sensor glucose values above 180mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters changes</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change in glycemic parameters: mean time of sensor glucose values above above 250mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters changes</measure>
    <time_frame>0-6 months</time_frame>
    <description>To evaluate the change in glycosylated haemoglobin (HbA1c)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>MiniMed™ 780G System</arm_group_label>
    <description>Subject will use the MiniMed™ 780G System as per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiniMed™ 780G System</intervention_name>
    <description>Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.</description>
    <arm_group_label>MiniMed™ 780G System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 7 years of age or older with T1D and under Continuous Subcutaneous Insulin&#xD;
        Infusion (CSII) therapy (with or without CGM)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥7 years of age.&#xD;
&#xD;
          2. Subject has a clinical diagnosis of type 1 diabetes for more than 1 year as determined&#xD;
             via medical records or source documentation by an individual qualified to make a&#xD;
             medical diagnosis.&#xD;
&#xD;
          3. Subject has a HbA1c value greater than 6.5% and less than 12% at time of enrolment&#xD;
             visit.&#xD;
&#xD;
          4. Subject is under Continuous Subcutaneous Insulin Infusion (CSII) therapy (with or&#xD;
             without Continuous Glucose Monitoring) ≥ 6 months before enrolment.&#xD;
&#xD;
          5. Subject requires ≥8 units of insulin per day.&#xD;
&#xD;
          6. Subjects and their parent(s)/guardian(s) must be able to speak and be literate in&#xD;
             French as verified by the investigator.&#xD;
&#xD;
          7. Subjects and their parent(s)/guardian(s) are willing to participate in the study and&#xD;
             sign the Data Release Form (DRF).&#xD;
&#xD;
          8. Subjects who are ≥18 years of age should be able to provide consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has MiniMed™ 780G System IFU contraindication(s).&#xD;
&#xD;
          2. Subject uses Predictive Low-Glucose Management (PLGM) System (i.e. MiniMed™ 640G with&#xD;
             SmartGuard) in the last 6 months before the enrolment.&#xD;
&#xD;
          3. Subject uses Low Glucose suspend (LGS) feature (i.e. MiniMed™ Paradigm Veo Pump) in&#xD;
             the last 6 months before the enrolment.&#xD;
&#xD;
          4. Subject under Multiple-Daily Injections (MDI) treatment in the 6 months before the&#xD;
             enrolment.&#xD;
&#xD;
          5. Subject has any unresolved adverse skin condition in the area of sensor placement&#xD;
             (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux (Saint-André)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Boulogne-Sur-Mer</name>
      <address>
        <city>Boulogne-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Groupement Hospitalier Est</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL DIAB-eCARE</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDNC Chartres</name>
      <address>
        <city>Mainvilliers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Marseille (Hôpital de la Conception)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM Marseille (La Timone)</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHEF (Centre Hospitalier de Meaux)</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier (Lapeyronie)</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Lariboisiere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Périgueux</name>
      <address>
        <city>Périgueux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse (Rangueil)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>780G, T1D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

